Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P58418
UPID:
CLRN1_HUMAN
Alternative names:
Usher syndrome type-3 protein
Alternative UPACC:
P58418; D3DNJ3; E1ACU9; Q8N6A9
Background:
Clarin-1, alternatively known as Usher syndrome type-3 protein, plays a pivotal role in the auditory and visual systems. It is instrumental in the formation of excitatory ribbon synapse junctions between hair cells and cochlear ganglion cells, as well as in the retina. This protein's unique function underscores its importance in sensory information processing.
Therapeutic significance:
Clarin-1 is directly implicated in Usher syndrome 3A and Retinitis pigmentosa 61, both of which are characterized by severe sensory impairments. Given its crucial role in these conditions, targeting Clarin-1 could lead to innovative treatments for these debilitating diseases, offering hope for improved quality of life for affected individuals.